Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments

  • Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. doi: 10.1073/pnas.1705234114.
Hirofumi Ohashi  1  2 ,  Yoshiki Koizumi  3 ,  Kento Fukano  1  4 ,  Takaji Wakita  1 ,  Alan S Perelson  5 ,  Shingo Iwami  6  7  8 ,  Koichi Watashi  9  2  8
Affiliations
  • 1. Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • 2. Department of Applied Biological Sciences, Tokyo University of Science, Noda 278-8510, Japan.
  • 3. School of Medicine, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa 920-8640, Japan.
  • 4. Department of Analytical Biochemistry, Meiji Pharmaceutical University, Kiyose 204-8588, Japan.
  • 5. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.
  • 6. Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan; [email protected] [email protected].
  • 7. Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan.
  • 8. Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan.
  • 9. Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; [email protected] [email protected].
PMID: 28512226 DOI: 10.1073/pnas.1705234114
Products